9th Market Access, Pricing & Reimbursement Global Congress 2023 Europe

Trends and Strategies to Achieve Optimum Patient Access to Healthcare

Hilton London Kensington Hotel, London, UK
  • 00Days
  • 00Hours
  • 00Minutes
  • 00Seconds

Market Access, Pricing & Reimbursement Programmes

Dear Colleagues,

On a global scale, the pharmaceutical market is expected to grow in the years to come regardless of a recent slowdown in key markets across the globe. The increase is exacerbated by the growing and ageing population in key markets. Aside from this, increasing access to Pharmaceuticals to poor and middle-class families due to increases in disposable income also drives the industry’s growth. Pharma companies focusing on Rare and speciality medicines is another aspect leading the growth. Innovations attracting investments even from non-pharma companies are also sustaining the growth in the pharmaceutical industry.

The pharmaceutical industry is one of the major players in the healthcare sector. Payers want to provide access and fund innovative treatments to improve patient care but governments across Europe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending due to the increasing pressure between the demands of the EU, national governments and regional authorities.

As healthcare budgets are continuously rising in Europe, governments implement a wide variety of policies to control them with the help of different public regulatory bodies that are involved in pharmaceutical coverage decisions across Europe. International collaboration among HTA and regulatory bodies can promote knowledge exchange, as do the actions payers take in an effort to reduce costs while maintaining quality care.

The upcoming 2023 Market Access, Pricing and Reimbursement Global Congress Europe will present a dynamic approach to key trends and insights on market access, health
technology assessment, real-world data, patient access, pricing and reimbursement on the current European landscape.

This year, we are putting together an agenda that addresses “Trends and Strategies to Achieve Optimum Patient Access to Healthcare”. We are gathering together high calibre expert speakers to participate and share their knowledge and expertise through Keynote Presentations and Panel discussions, addressing all aspects of the industry.

We look forward to welcoming you to the MAPR 2023 congress!

Sincerely yours,

Jocelyn Raguindin
Jocelyn Raguindin

Jocelyn is Conference Director at Paradigm Global Events (PGE). She has over 15+ years experience in organizing pharma-industry conferences and has been at the helm of every PGE conference since 2013. Jocelyn is based in London, UK.

Why you should attend:


You Will Meet:


Network with members of boards, VP’s, Directors, Heads/Chiefs and Senior Managers of leading biopharmaceutical and biotech companies, government, CRO and solution providers involved in:

0 +
days Congress
0 +
0 +

Key Industry Expert Speakers

2023 Speakers 

Claudia Neuber,

Head, Global Pricing Oncology, Global Market Access & Pricing


Daniel Jackson

Global Head - Market Access Policy


Silvy Mardiguian

Market Access Director, UK & Ireland


Ana Plata

Global Pricing Head - BioPharmaceuticals


Dr. Marco Rauland

Vice President, Global Value Demonstration, Market Access & Pricing

Merck KGaA

Maarten Van Baelen

Executive Director

Plasma Protein Therapeutics Association

Laura A Clark-Kelly

Sr. Director

Bayer Pharmaceuticals

Elvira Müller

Vice President

Certara Evidence & Access


Global Market Access Academy Lead



Founder and CEO

Decisive Consulting Ltd.


Global Pricing Implementation Lead



Director Market Access

IGES U.K. Pharma Ltd


Content Rich Program Agenda!  Featuring Keynote Presentations, Stream Sessions, Panel, and Round Table Discussions.


  • Trends that will continue to impact, Market Access, Pricing and Reimbursement in healthcare
  • Unlocking data from early access
  • Effective communications with internal and external stakeholders
  • Embracing the digital vision
  • Future trends and developments in the healthcare distribution
  • Looking into increase cross-border collaboration as a potential means of controlling cost
  • Addressing unfair access to medicines
  • Enhancing the drive for greater price transparency
  • Focus on outcomes-based reimbursement and innovative funding mechanisms
  • Current trends in parallel advice: What has changed?
  • Importance of seeking early regulatory, HTA, and joint consultation
  • Risk and advantages of using parallel consultation at the EU or national level?
  • Successful strategies to maximise the benefit of parallel consultation


Santoke Naal, Director Market Access, IGES U.K. Pharma Ltd

  • New landscape for risk-sharing agreements among manufacturer, payer and patients
  • Understand the benefits of a good collaboration between payers and pharma companies to ensure patient access
  • What do the decision-makers on drug usage think today about how the industry is responding to the immense challenges it is facing?
  • Addressing the factors that made the launch environment more challenging
  • Capabilities needed for an effective drug launch
  • How to best leverage outsourced partners to achieve success.
  • Best practices to achieve successful commercialisation.
  • Challenges and obstacles in bringing this highly complex therapies to market
  • Stakeholder collaboration on the road towards a solution
  • Lessons learned and applications for new entrants
  • Strategies that can be taken to improve timely market access and access for patients
  • The Do’s and Don’ts of contractual negotiations
  • The role of real-world evidence
  • How to find the right endpoints for outcome-based agreements
  • Recognize the potential of Personalized Medicine in Oncology / Cancer Patients benefits;
  • Identify challenges which could be encountered during HTA process;
  • Develop strategies to overcome or to remove any barrier for Patient Access to Precision Oncology
  • Latest legislation and impact
  • Market Access at national level
  • Developments at regional level
  • Outlook 2023
  • Overview of current considerations around orphan drug assessment
  • Recent and expected trends around evolution of assessment criteria
  • Anticipated impact on evaluation of orphan drugs in German
  • Overall perception of orphan drug commercial opportunity due to assessment trends
  • Regulatory challenges following Brexit and its effect
  • Steps taken by MHRA to alleviate the effects of leaving the European regulatory network.
  • Understanding the current state of pharmaceutical sector
  • Addressing the priorities for negotiations
  • The ability of UK citizens to access new medications

Networking Drinks Reception


  • Advantages of market access teams in payer relationship
  • Payer evidence requirement in early development
  • Best practices to obtain better pricing and reimbursement
  • Strategies to improve a better payer relationship

Claudia Neuber, Head, Global Pricing Oncology, Global Market Access & Pricing, AstraZeneca

  • Why is this important?
  • Current state of play
  • Barriers to Equity Pricing
  • Potential solutions and some principles to maximize impact of Equity Pricing
  • Innovative approaches required to address the medicine access challenge
  • Lessons to be learned from best practices in the field of pricing and reimbursement of medicines
  • The value of list prices against the backdrop of external price referencing and managed entry agreements.
  • Innovative policy options that needs to be developed, agreed upon and implemented.
  • Keeping on top of pricing and market access trends
  • Identify a clinical or economic advantage and generate the appropriate clinical and health economic evidence to support a strong value proposition
  • Optimising the use of Patient-Reported Outcomes
  • Unlocking data from early access
  • Effective communications with internal and external stakeholders
  • Embracing the digital vision
  • Challenges in drug pricing and reimbursement
  • How to navigate a complex balance between financial and strategic risks
  • Strategies to offset regulatory and inflationary pressures.
  • Addressing environmental, social, and corporate governance issues
  • Encouraging cross-functional or cross-company collaborations
  • The increasing relevance of Emerging Markets
  • EMs Embrace Technological Innovation
  • Creating value through partnership
  • How to Avoid the Pitfalls of Innovation in Emerging Markets
  • Objective: Activating the full stakeholder ecosystem to shift conversation from price to value to get access to innovative therapies
  • Why is the full stakeholder ecosystem important for gaining access in the future?
  • How to Identify the stakeholder ecosystem for access success
  • Step by step: Setting up a cross-functional program for access success
  • Assessment of financial benefit from tendering
  • Evaluating its impact on prices and market concentration
  • Consideration of its operational framework
  • Tendering for pharmaceuticals as a reimbursement tool
  • The importance of making MA the core of the company
  • Bridge between pre-launch strategy and post-launch
  • International Drug Price Indicator Guide WHO
  • Increasing collaboration between EU countries
  • Frontiers in Health Care
  • What will the future bring?


This year’s 9th Market Access, Pricing & Reimbursement Global Congress 2023 Europe, will be co-located with the 2nd Real-World Evidence World Congress 2023 Europe. 

Sponsors & Exhibitors will have the opportunity to Network with Attendees from both Events. 

Website: https://realworldevidencecongress.com/

Newsletter Sign Up

No Spam - You will only receive relevant information on Patient Centricity & Collaboration, and event updates


what people say

Thank you for a good experience with the PARADIGM Global Events… very high level, very good Organization, we overpassed our expectatives, we will be pending for another congress related to pharmaceutical and biotech… we learned a lot, and i think that the content of agenda was state of the art, thank you again.
Salvador Berrios
ERP/ CRM / Product Configurator Manager
The consistently high quality of international faculty was most impressive. It was also obvious that they were carefully chosen not only for their particular expertise but also for their ability to communicate the subject matter to clinical and non-clinical participants alike. As market access consultant for pharma clients of various sizes, I now feel much better prepared to explain the nuances & dynamics involved in bringing their products to market. In addition, I am in a much better position to intelligently advice my clients & help them set realistic expectations
Thomas Martin
Associate Vice President, VCGA - Quintiles
I was impressed with the organization of this event. I attend many conferences per year and find the organizers on site to be detached and not focus on good service to the delegates. This team was even providing weather forecast warning to ensure everyone was aware and made appropriate plans. Well Done.
Adriana E. Manzi
PhD, Managing Director, Atheln, Inc

Previous events

Book Your Place Now! 

Register To Attend Now!

Take Advantage of the Super Early Bird Discount. Group Discounts Also Available. 


Scroll to Top
Scroll to Top